Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eleonora Cioli
Observed names:
Cioli, Eleonora,
E. Cioli
Institutions:
University of Campania "Luigi Vanvitelli",
Agostino Gemelli University Polyclinic,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Istituti di Ricovero e Cura a Carattere Scientifico,
European Institute of Oncology
Observed institutions:
University of Campania "Luigi Vanvitelli",
Agostino Gemelli University Polyclinic,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Istituti di Ricovero e Cura a Carattere Scientifico,
European Institute of Oncology
ORCID:
0000-0002-8788-6574
Observed ORCID:
0000-0002-8788-6574
OpenAlex ID:
A5021417883
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
2023
·
Domenico Mallardo
, Ester Simeone
, et al.
·
Journal of Translational Medicine
·
24
PDF
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives
2025
·
Stefania Napolitano
, Davide Ciardiello
, et al.
·
Cancer Treatment Reviews
·
20
PDF
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
2024
·
Domenico Mallardo
, Francesca Sparano
, et al.
·
Cancer Immunology Immunotherapy
·
16
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial
2025
·
D. Ciardiello
, L. Boscolo Bielo
, et al.
·
ESMO Open
·
15
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
2023
·
Claudia Trojaniello
, Francesca Sparano
, et al.
·
Current Oncology Reports
·
15
PDF
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study
2025
·
Davide Ciardiello
, Luca Boscolo Bielo
, et al.
·
European Journal of Cancer
·
11
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for
2024
·
Sara Parola
, Christoph Oing
, et al.
·
Frontiers in Genetics
·
10
PDF
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma
2024
·
Vincenzo De Falco
, Stefania Napolitano
, et al.
·
OncoImmunology
·
8
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
2023
·
Paolo A. Ascierto
, Eleonora Cioli
, et al.
·
Frontiers in Oncology
·
4
PDF
New clinical needs in melanoma staging: is there still room for single lymph node excision?
2025
·
F. Caraglia
, T. Troiani
, et al.
·
Annals of Research in Oncology
·
2
PDF
Systemic Therapies for Advanced Hepatocellular Carcinoma: Which Gaps Should We Try to Fill?
2025
·
Eleonora Cioli
, Lorenzo Gervaso
, et al.
·
JCO Oncology Practice
·
2
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center’s real-world approach
2025
·
E. Cioli
, G. Suarato
, et al.
·
ESMO Real World Data and Digital Oncology
·
2
PDF
Impact of sex on immune-related adverse events in patients with melanoma.
2024
·
Margaret Ottaviano
, Domenico Mallardo
, et al.
·
Journal of Clinical Oncology
·
1
PDF
579 Evaluation of cemiplimab treatment duration: clinical outcomes in advanced CSCC
2023
·
Domenico Mallardo
, Francesca Sparano
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
3543P Early- versus late-onset locally advanced rectal cancer clinical characteristics and outcomes from the TRACER study
2026
·
R.M. Marsicano
, G. Malvezzi
, et al.
·
Annals of Oncology
2143eP ctDNA and cfMeDip as a tool to predict response in metastatic melanoma patients under anti-PD1+anti-CTLA4 treatments
2026
·
F. Caraglia
, E. Cioli
, et al.
·
Annals of Oncology
Immune Checkpoint Inhibitor Data in Metastatic Melanoma with Pre-Existing Autoimmune Disease: A Real World Experience
2026
·
Maria Grazia Vitale
, Domenico Mallardo
, et al.
·
International Journal of Molecular Sciences
Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study
2026
·
Vincenzo De Falco
, Antonino Colloca
, et al.
·
Cancer Immunology Immunotherapy
PDF
Management of cancer-associated thrombosis in patients with gastrointestinal cancers: lights and shadows
2026
·
Lorenzo Gervaso
, Eleonora Cioli
, et al.
·
Cancer Treatment Reviews
Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study
2026
·
Francesco Caraglia
, Giuseppe Argenziano
, et al.
·
Frontiers in Immunology
PDF
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
2026
·
D. Ciardiello
, L. Boscolo Bielo
, et al.
·
ESMO Gastrointestinal Oncology
PDF
13P Integrating tissue (TBx) and liquid biopsy (LBx) comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer (mCRC): Findings from the CAPRI-2 GOIM study
2025
·
E. Cioli
, L. Boscolo Bielo
, et al.
·
Annals of Oncology
PDF
37P Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
2024
·
A. Esposito
, L. Amato
, et al.
·
ESMO Open
Gene signature to predict hypophysitis in patients with melanoma treated with anti-PD-1 in adjuvant setting.
2024
·
Ester Simeone
, Domenico Mallardo
, et al.
·
Journal of Clinical Oncology
42 IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy – a deep biomarker analysis
2023
·
Domenico Mallardo
, Sergio Arpino
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
34
Citation count:
131
H-index:
8
I10-index:
7
Year
Topic
Type